Dementia and Alzheimer Disease

Expert neurologists, Richard S. Isaacson, MD, and Marc E. Agronin, MD, describe the journey to the FDA approval of aducanumab for the treatment of Alzheimer disease and what this means for clinicians.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 11, 2021.

Alzheimer disease experts Richard S. Isaacson, MD, and Marc E. Agronin, MD, discuss the recent aducanumab approval and some of the clinical community's concerns.

The nurse practitioner at the Woodruff School of Nursing at Emory University detailed why advanced practice clinicians should be utilized more in neurology settings.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive look into the FDA approval of aducanumab (Aduhelm; Biogen) for the treatment of Alzheimer disease.

Ian Kremer, executive director of the LEAD Coalition, discusses the need for improved access to social services surrounding the diagnosis and management of Alzheimer disease.

Experts in the treatment and management of patients with Alzheimer disease and dementia, including Marwan Sabbagh, MD; Lon Schneider, MD, MS; Anton Porsteinsson, MD; and Robert Howard, MD, MRCPsych, weigh in on the FDA's controversial approval of Biogen's anti-amyloid drug, aducanumab.

The FDA has approved Biogen’s disease-modifying, anti-amyloid agent aducanumab after a tumultuous regulatory journey.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending June 5, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 4, 2021.

AC Immune SA also continues to develop an improved formulation of the investigational agent.

Recommendations for exploratory trial designs may help clinicians be more confident in making the all-important go/no-go decisions about advancing drugs to larger later-stage trials.

Through surveys and an international meeting, the International Society for CNS Clinical Trials Methodology developed consensus criteria for NCD-specific apathy.

Identified by Mayo Clinic investigators, the protein-coding gene SERPINA5 was found to be associated with tau expression, characteristic of Alzheimer disease pathology.

Here's what is coming soon to NeurologyLive.

Richard Gershon, PhD, vice chair for research at the Northwestern University Feinberg School of Medicine, discussed the development of the mobile toolbox battery to track cognitive decline.

Neurology News Network for the week ending May 29, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 28, 2021.

With successful completion of the phase 2a study, Annovis plans on evaluating ANVS401 in late-stage studies starting in late 2021.

Here's what is coming soon to NeurologyLive.

The findings suggest that patients with dementia should be prioritized for stringent preventive measures, greater surveillance, and early intervention in COVID-19.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 21, 2021.

Acute encephalopathy, coma, and stroke were among clinically diagnosed neurological symptoms that increased mortality risk in patients with COVID-19.

The vice chair for research at the Northwestern University Feinberg School of Medicine discussed the potential of the mobile toolbox battery to screen hundreds of thousands for cognitive impairment.

Here's what is coming soon to NeurologyLive.

The vice chair for research at the Northwestern University Feinberg School of Medicine discussed creating a mobile cognitive toolbox to be used by all populations.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 14, 2021.

Clive Ballard, MD, the executive dean at the University of Exeter Medical School, discussed the safety and efficacy profile of pimavanserin (Nuplazid; Acadia Pharmaceuticals).